Zymeworks Inc. (NASDAQ:ZYME – Get Free Report)’s share price rose 4.9% during mid-day trading on Thursday. The company traded as high as $27.43 and last traded at $27.3120. Approximately 226,922 shares changed hands during mid-day trading, a decline of 71% from the average daily volume of 785,557 shares. The stock had previously closed at $26.04.
Analyst Upgrades and Downgrades
A number of research analysts have recently weighed in on ZYME shares. Stifel Nicolaus set a $46.00 price target on Zymeworks in a research report on Friday, August 7th. Truist Financial upped their target price on Zymeworks from $35.00 to $36.00 and gave the company a “buy” rating in a research note on Tuesday, November 10th. Wolfe Research started coverage on shares of Zymeworks in a report on Thursday, September 17th. They issued an “outperform” rating on the stock. JPMorgan Chase & Co. raised their price target on shares of Zymeworks from $31.00 to $33.00 and gave the company an “overweight” rating in a report on Thursday, September 3rd. Finally, Jefferies Financial Group reiterated a “buy” rating and set a $52.00 price objective on shares of Zymeworks in a research note on Friday, October 23rd. Twelve equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Zymeworks currently has a consensus rating of “Moderate Buy” and an average target price of $43.25.
Get Our Latest Analysis on ZYME
Zymeworks Price Performance
The business has a fifty day moving average price of $27.20 and a 200 day moving average price of $25.53. The company has a market capitalization of $1.85 billion, a price-to-earnings ratio of 51.64 and a beta of 1.32.
Zymeworks (NASDAQ:ZYME – Get Free Report) last posted its quarterly earnings data on Monday, November 9th. The company reported $2.28 earnings per share for the quarter, topping the consensus estimate of $2.27 by $0.01. Zymeworks had a net margin of 16.10% and a return on equity of 22.23%. The business had revenue of $512.92 million during the quarter, compared to the consensus estimate of $227.40 million. During the same quarter in the prior year, the company posted ($0.26) earnings per share. The company’s quarterly revenue was up 828.7% compared to the same quarter last year. Research analysts anticipate that Zymeworks Inc. will post 1.31 earnings per share for the current year.
Zymeworks declared that its board has authorized a stock repurchase program on Monday, November 16th that permits the company to buy back $200 million in shares. This repurchase authorization permits the company to reacquire up to 10.9% of its shares through open market purchases. Share repurchase programs are usually an indication that the company’s leadership believes its stock is undervalued.
Insider Transactions at Zymeworks
In other Zymeworks news, insider Paul Moore sold 39,741 shares of the firm’s stock in a transaction dated Friday, November 13th. The stock was sold at an average price of $26.07, for a total transaction of $1,036,047.87. Following the completion of the sale, the insider directly owned 33,756 shares in the company, valued at approximately $880,018.92. This trade represents a 54.07% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Adam Schayowitz sold 13,832 shares of the business’s stock in a transaction on Friday, October 9th. The shares were sold at an average price of $25.85, for a total transaction of $357,557.20. Following the transaction, the executive vice president owned 23,205 shares in the company, valued at approximately $599,849.25. This represents a 37.35% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 37.73% of the company’s stock.
Institutional Trading of Zymeworks
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. BlackRock Inc. bought a new position in Zymeworks during the second quarter valued at about $111,122,000. Rubric Capital Management LP raised its position in Zymeworks by 21.7% in the 1st quarter. Rubric Capital Management LP now owns 7,000,000 shares of the company’s stock worth $175,280,000 after purchasing an additional 1,250,000 shares during the last quarter. Fisher Asset Management LLC lifted its position in Zymeworks by 759.9% during the 3rd quarter. Fisher Asset Management LLC now owns 608,612 shares of the company’s stock valued at $16,122,000 after purchasing an additional 537,837 shares during the period. Assenagon Asset Management S.A. increased its holdings in Zymeworks by 72.0% in the second quarter. Assenagon Asset Management S.A. now owns 1,252,027 shares of the company’s stock valued at $32,728,000 after purchasing an additional 524,041 shares during the last quarter. Finally, Goldman Sachs Group Inc. increased its position in shares of Zymeworks by 102.7% during the third quarter. Goldman Sachs Group Inc. now owns 954,409 shares of the company’s stock worth $25,282,000 after acquiring an additional 483,587 shares in the last quarter. Institutional investors and hedge funds own 92.89% of the company’s stock.
About Zymeworks
Zymeworks Inc. is a biotechnology company headquartered in Vancouver, Canada, that develops engineered medicines, with a focus on treatments for cancer and other serious diseases. Its antibody-engineering technologies are designed to create therapies that can engage multiple biological targets or modify immune responses. The company’s lead program is zanidatamab, a HER2-targeted bispecific antibody. In the United States, it is marketed by partner Jazz Pharmaceuticals as Ziihera for certain adults with previously treated, unresectable or metastatic biliary tract cancer.
Recommended Stories
- Five stocks we like better than Zymeworks
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Zymeworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zymeworks and related companies with MarketBeat.com's FREE daily email newsletter.
